Skip to main content
Premium Trial:

Request an Annual Quote

Kevin King, Gregory Schiffman, James Gibson, John Quackenbush, David Liu, Bob Tepper, Anthony Simonetta, Robert Gottlieb

Gregory Schiffman has left his various senior executive positions at Affymetrix to take on the role of senior vice president and chief financial officer at Dendreon, a Seattle-based drug developer.
Affymetrix said last week that Schiffman resigned, effective immediately, from his posts as executive vice president, CFO, and treasurer, as well as other positions he holds at Affy subsidiaries.
The company said James Gibson, 37, will take over the role of principal accounting officer from his position as vice president of accounting and corporate controller. Gibson formerly served as director of finance and controller at Netflix.
Affy said it intends to start seeking candidates for the CFO and principal financial officer immediately.
Before working at Affymetrix, Schiffman held vice president positions at Applied Biosystems, Hewlett Packard, and IBM.
Affymetrix also announced this week that Kevin King was appointed president of its life sciences business. Formerly president and CEO of Thompson Healthcare, King will report to Affy CEO Stephen Fodor.  

Next-generation sequencing company Helicos Biosciences said last week it has added John Quackenbush and David Liu to its scientific advisory board.
Quackenbush is a professor of biostatistics and computational biology at the Dana-Farber Cancer Institute and is professor of biology and bioinformatics at HarvardUniversity’s School of Public Health.
Liu is professor of chemistry and chemical biology at Harvard University, and is an associate member of the Broad Institute of Harvard and Massachusetts Institute of Technology.

Millennium Pharmaceuticals last week said Bob Tepper, president of its research and development division, will leave the company in the first quarter of 2007. Millennium said Tepper was one of the company’s founding members, having been there since 1994.
Millennium said it is currently seeking a successor.

Custom antibody designer Strategic Diagnostics last week said Chief Financial Officer Anthony Simonetta has resigned to “pursue other opportunities.”
The company said it will begin a search for a new CFO immediately.

IntegraGen has appointed Robert Gottlieb to serve as CEO of the company’s US expansion effort, the firm said last week.
Gottlieb will take the helm at IntegraGen, Inc., which will be based in New York. He will continue to serve the parent company as vice president of global sales and marketing.
Gottlieb has worked at Abbott Laboratories, General Electric, Becton Dickinson, and Roche Diagnostics.


Note to Readers: This is the last issue of Pharmacogenomics Reporter to publish in 2006. The next issue of the newsletter will appear on Wednesday, Jan. 3.

Filed under

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.